Business Context and Reporting Period
Company: Ocular Therapeutix, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 31, 2023
Reporting Period: The filing reports on a specific event occurring on March 31, 2023, regarding an amendment to a credit agreement.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, or liquidity ratios. The document focuses exclusively on a contractual amendment to the company's debt facility.
Material Changes
The Company entered into an amendment to its Fourth Amended and Restated Credit and Security Agreement with MidCap Financial Trust and other lenders. The material changes include:
- Replacement of LIBOR-based interest rate provisions with SOFR-based interest rate provisions.
- Establishment of a benchmark replacement mechanism.
- Implementation of additional administrative updates.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, or discussion of general business risks. The primary contingency noted is the transition of the interest rate benchmark from LIBOR to SOFR. The full text of the Amendment is referenced as an exhibit to be filed in the subsequent Form 10-Q for the quarter ending March 31, 2023.
Investor Verification Checklist
- Verify the specific SOFR spread and interest rate terms in the full Amendment text (to be filed in the Q1 2023 Form 10-Q).
- Confirm the total outstanding principal balance under the amended Credit and Security Agreement.
- Review the impact of the benchmark replacement on future interest expense projections.